Recent Updates — VNDA

Vanda Pharmaceuticals reported third-quarter 2026 total net product sales of $69.8 million, a 24% increase from the prior year period and a 38% rise compared to Q2 2026. Operating expenses decreased by 18% sequentially to $93.3 million as key Phase III and launch-preparation activities concluded. The company announced positive results from the Phase III study of NEREUS for preventing GLP-1-induced vomiting, with plans to submit a supplemental New Drug Application. Additionally, Vanda updated its full-year 2026 financial guidance, expecting total revenue to exceed $240 million. The firm operates in the biopharmaceutical industry, developing and commercializing innovative therapies for high unmet medical needs.

Vanda Pharmaceuticals Inc. reported second quarter 2026 financial results, announcing total net product sales of $50.5 million and a net loss of $62.5 million, or $1.04 per diluted share. Fanapt net product sales increased 23% to $36.0 million, while HETLIOZ sales declined 66% to $5.6 million. The company reiterated its full-year 2026 total revenue guidance of $240 million to $290 million and reported cash reserves of $170.0 million as of June 30, 2026. Vanda operates in the biopharmaceutical industry, developing and commercializing innovative therapies for neurological and psychiatric disorders.